Healthcare Industry News: hemodialysis
News Release - November 27, 2006
NxStage Medical, Inc. Appoints Robert S. Brown as Chief Financial OfficerLAWRENCE, Mass., Nov. 27 (HSMN NewsFeed) -- NxStage Medical, Inc. (Nasdaq: NXTM ) today announced the appointment of Robert S. Brown as Chief Financial Officer effective immediately. In this role, he will manage the company's financial strategy and administration reporting directly to Jeffrey H. Burbank, President & Chief Executive Officer of NxStage.
"We are pleased to have attracted an experienced industry player like Robert to our company at this exciting time in our development," said Jeff Burbank. "In addition to relevant expertise gained at one of the world's leading medical technology companies, Robert brings proven leadership in strategic planning, risk management and compliance. We welcome Robert to NxStage."
Robert S. Brown joins NxStage with more than 20 years of financial experience. Prior to joining NxStage, Mr. Brown held several leadership positions in Boston Scientific's financial group including Vice President, Corporate Analysis & Control where he and his team were responsible for the company's financial, compliance and operational audits and reported directly to the Audit Committee of the Board of Directors. Mr. Brown also served as Vice President, International where he was responsible for the financial functions of Boston Scientific's $2.5 billion international division in over forty countries. Previous experience also includes financial reporting and special projects at United Technologies and public accounting and consulting at Deloitte & Touche. Mr. Brown earned his M.B.A. at The University of Michigan, his B.B.A. at The University of Toledo and is a Certified Public Accountant.
"I strongly believe in the NxStage product platform and its mission to transform renal care by expanding treatment options," said Robert Brown. "I am thrilled to be joining such an innovative and dynamic team."
Mr. Brown fills the vacancy left following David N. Gill's announcement of his intention to resign from the position of Chief Financial Officer last spring. Mr. Gill had agreed to continue to work for the company until his replacement could be found. "We are grateful for the tremendous contributions made by David and appreciate his willingness to support us during this transition period," said Mr. Burbank. "David brought significant financial and medical device experience to the NxStage team. We are fortunate to have worked with him and to have found such a high-quality successor to fill his position."
About NxStage Medical:
NxStage Medical, Inc. (Nasdaq: NXTM ) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative dialysis systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for home hemodialysis products, including NxStage's products, and the anticipated benefits of more frequent and home hemodialysis. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for home hemodialysis technologies, including the NxStage System One, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Source: NxStage Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.